Yes, Medicare generally covers bone growth stimulators, but coverage is strictly regulated and contingent upon meeting precise medical necessity criteria. For example, Medicare Part B typically covers non-invasive osteogenesis stimulators for specific conditions, such as spinal fusion surgeries with failed healing histories or stubborn long-bone non-union fractures that have failed standard conservative management over a prolonged period, backed by complete physician documentation.
Orthofix Inc. previously faced high-profile federal scrutiny and a major whistleblower False Claims Act lawsuit that resulted in a $42 million global criminal and civil resolution with the U.S. Department of Justice.
The President and Chief Executive Officer of Orthofix Medical Inc. is Massimo Calafiore, who also serves as a member of the company's Board of Directors.
In orthopedic and medical device contexts, specialized systems carrying similar names are deployed to stimulate bone healing.
The Ofix 200 Tablet is a prescription fluoroquinolone antibiotic containing 200mg of ofloxacin as its active pharmaceutical ingredient.
Supporting bone fracture healing and overall skeletal health through nutrition requires adequate intake of calcium, protein, and essential micronutrients.
Clinical and scientific evidence demonstrates that Orthofix's medical devices and orthopedic systems achieve high rates of clinical efficacy when utilized according to strict manufacturer guidelines and physician instructions.
Revo Health operates as a prominent management services organization partnering with specialized healthcare practices like Twin Cities Orthopedics.
Orthofix Medical Inc.
Orthofix Medical Inc.
The "best" bone growth stimulator is determined by a physician's prescription based on the specific type of fracture, non-union status, or spinal fusion site.
When referring to pharmaceutical products like the OFIX tablet (which contains the fluoroquinolone antibiotic ofloxacin), potential side effects can include gastrointestinal discomfort such as nausea, mild diarrhea, abdominal cramps, headaches, dizzi...
The out-of-pocket rental cost for a prescription bone growth stimulator varies significantly depending on health insurance coverage, Medicare provider fee schedules, and specific device models.
Orthofix Medical Inc. maintains its primary corporate headquarters and executive administrative offices in Lewisville, Texas, United States.
Wall Street equity research analysts covering Orthofix Medical Inc. (NASDAQ: OFIX) maintain a general consensus rating leaning toward a Buy.
The global orthopedic and medical device market features several massive multinational corporations competing for top market share.
Orthofix Medical Inc. maintains a dedicated global workforce comprising approximately 1,300 to 1,600 employees worldwide.
No, Orthofix Medical Inc. is not a private company. It is a publicly traded global medical technology enterprise listed on the Nasdaq Global Select Market under the ticker symbol OFIX.
When discussing medical devices or orthopedic care frameworks, "Safix" (or similar variant terminology associated with casting, bandaging, or stabilization products) typically presents minimal localized risks.
Depending on the context of your inquiry, OFIX can refer to multiple distinct entities. In financial markets, OFIX is the ticker symbol for Orthofix Medical Inc.
The financial cost of an Orthofix bone growth stimulator varies substantially depending on whether the device is rented or purchased, insurance contract terms, and specific Medicare fee schedules.
Orthofix Medical Inc. (NASDAQ: OFIX) generates robust annual net revenues scaling in the hundreds of millions of dollars, typically reporting total yearly revenues between $700 million and $750 million.
Bone growth stimulators are generally considered exceptionally safe medical devices with minimal adverse side effects.
The cost of an Orthofix bone growth stimulator (such as their proprietary spine or extremity therapy units) varies depending on insurance contractual agreements, Medicare fee schedules, and whether the device is rented or purchased.
Yes, Medicare generally covers non-invasive bone growth stimulators, but authorization is strictly contingent upon meeting precise medical necessity criteria.
Yes, Orthofix's core medical devices and bone growth therapy systems are FDA approved or cleared for commercial distribution and clinical use in the United States.